Everolimus + Octreotide LAR

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Polycystic Liver Disease

Conditions

Polycystic Liver Disease

Trial Timeline

Jun 1, 2010 → Jul 1, 2012

NCT ID

NCT01157858

About Everolimus + Octreotide LAR

Everolimus + Octreotide LAR is a phase 2 stage product being developed by Novartis for Polycystic Liver Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01157858. Target conditions include Polycystic Liver Disease.

What happened to similar drugs?

3 of 14 similar drugs in Polycystic Liver Disease were approved

Approved (3) Terminated (4) Active (7)

✅tredaptive (nicotinic acid/ laropiprant) + placeboMerckApproved

✅Placebo + EverolimusNovartisApproved

✅3 mg DRSP/20 μg EEBayerApproved

🔄Metformin XR + Saxagliptin + Saxagliptin-Metformin XRAstraZenecaPhase 3

🔄Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ERAstraZenecaPhase 3

🔄Lisinopril + Telmisartan + PlaceboMerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01157858	Phase 2	Completed	Jun 1, 2010	Jul 1, 2012	Polycystic Liver Disease

Competing Products

20 competing products in Polycystic Liver Disease

See all competitors

Product	Company	Stage	Hype Score
Tildacerfont + Placebo	Spruce Biosciences	Phase 2	17
ABBV-CLS-628 + Placebo	AbbVie	Phase 2	42
Elagolix + Placebo	AbbVie	Phase 2	35
Metformin XR + Saxagliptin + Saxagliptin-Metformin XR	AstraZeneca	Phase 3	40
Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ER	AstraZeneca	Phase 3	40
AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part B	AstraZeneca	Phase 1	36
AZD4901 (oral) + Placebo to match AZD4901	AstraZeneca	Phase 2	35
IVF Antagonist Protocol	Merck	Pre-clinical	22
tredaptive (nicotinic acid/ laropiprant) + placebo	Merck	Approved	43
Lisinopril + Telmisartan + Placebo	Merck	Phase 3	40
Lisinopril + Telmisartan + Placebo	Merck	Phase 3	40
Cetrorelix acetate + Cetrorelix acetate + Recombinant Human Choriogonadotropin (r-hCG) + Recombinant human follicle stimulating hormone (r-hFSH)	Merck	Phase 3	40
Gonal-f® + Long GnRH agonist + GnRH antagonist	Merck	Pre-clinical	26
Placebo + Everolimus	Novartis	Approved	43
LIK066 + Placebo	Novartis	Phase 2	35
Octreotide + Placebo	Novartis	Phase 2/3	38
Everolimus + Calcineurin inhibitors maintenance	Novartis	Phase 3	40
Atorvastatin + Placebo	Pfizer	Pre-clinical	26
Rapamune	Pfizer	Phase 1/2	32
Sirolimus	Pfizer	Phase 2/3	34